Goodenough Christopher J, Liang Mike K, Nguyen Mylan T, Nguyen Duyen H, Holihan Julie L, Alawadi Zeinab M, Roth John S, Wray Curtis J, Ko Tien C, Kao Lillian S
Department of Surgery, University of Texas Health Science Center, Houston, TX.
Department of Surgery, University of Kentucky, Lexington, KY.
J Am Coll Surg. 2015 Oct;221(4):854-61.e1. doi: 10.1016/j.jamcollsurg.2015.07.013. Epub 2015 Jul 20.
Glycosylated hemoglobin (HbA1c) is diagnostic of and a measure of the quality of control of diabetes mellitus. Both HbA1c and perioperative hyperglycemia have been targeted as modifiable risk factors for postoperative complications. The HbA1c percent cutoff that best predicts major complications has not been defined.
A prospective study of all abdominal operations from a single institution from 2007 to 2010 was performed. All patients with HbA1c within 3 months before surgery were included. The primary end point was major complication, using the Clavien-Dindo complication system, within 30 days of surgery. Stepwise, multivariate analysis was performed including clinically relevant variables chosen a priori.
Among 438 patients who had a measured HbA1c, 96 (21.9%) experienced a major complication. On multivariate analysis, HbA1c ≥ 6.5% (odds ratio = 1.95; 95% CI, 1.17-3.24; p = 0.01) was found to be the most significant predictor of major complications. Glyosylated hemoglobin and glucose were strongly correlated (correlation coefficient 0.414, p < 0.01). Predicted probabilities demonstrated that both HbA1c and glucose together contributed to major complications; and HbA1c impacted the ability to achieve optimal perioperative glucose control. Patients with a BMI >30 kg/m(2), history of coronary artery disease, and nonwhite race were more likely to have a HbA1c ≥ 6.5%.
Elevated HbA1c ≥ 6.5% and perioperative hyperglycemia were associated with an increased rate of major complications after abdominal surgery. Elevated peak postoperative glucose levels were correlated with elevated HbA1c and were independently associated with major complications. More liberal HbA1c testing should be considered in high-risk patients before elective surgery. Safe, feasible, and effective strategies to reduce both HbA1c and perioperative hyperglycemia need to be developed to optimize patient outcomes.
糖化血红蛋白(HbA1c)可用于诊断糖尿病并衡量糖尿病的控制质量。HbA1c和围手术期高血糖均已被视为术后并发症的可改变风险因素。尚未确定最能预测主要并发症的HbA1c百分比临界值。
对2007年至2010年来自单一机构的所有腹部手术进行了一项前瞻性研究。纳入所有术前3个月内有HbA1c检测值的患者。主要终点是采用Clavien-Dindo并发症系统评估的术后30天内的主要并发症。进行了逐步多变量分析,纳入了事先选定的临床相关变量。
在438例检测了HbA1c的患者中,96例(21.9%)发生了主要并发症。多变量分析发现,HbA1c≥6.5%(比值比=1.95;95%可信区间,1.17 - 3.24;p = 0.01)是主要并发症的最显著预测因素。糖化血红蛋白与血糖密切相关(相关系数0.414,p < 0.01)。预测概率表明,HbA1c和血糖共同导致主要并发症;并且HbA1c影响实现最佳围手术期血糖控制的能力。体重指数>30 kg/m²、有冠状动脉疾病史和非白人种族的患者更有可能HbA1c≥6.5%。
HbA1c≥6.5%升高和围手术期高血糖与腹部手术后主要并发症发生率增加相关。术后血糖峰值升高与HbA1c升高相关,且与主要并发症独立相关。对于高危患者,在择期手术前应考虑更广泛地检测HbA1c。需要制定安全、可行且有效的策略来降低HbA1c和围手术期高血糖,以优化患者预后。